Patient FAQs

Frequently Asked Questions

AlloMap® is a blood test. It helps your transplant team know if you are at a low risk for rejecting your new heart (known as acute cellular rejection). Your transplant team uses the AlloMap results to help manage your care.

AlloMap measures the levels of 20 genes in your blood. These genes have been identified as having a role in rejection. The levels of these genes are converted to an AlloMap test score. This score is reported on the AlloMap Report (shown below) and appears as an integer ranging from 0 to 40. The score reported is individual to you. Your transplant team uses your AlloMap test score, along with other standard tests, to find out how well your body is accepting your new heart. AlloMap may be used more frequently in the first year after your transplant, and may be used less frequently over time. Your transplant team can advise when AlloMap testing should be conducted.allomap_results_small

AlloMap is a non-invasive method to determine acute cellular rejection (ACR). The primary alternative to assess ACR is a biopsy procedure.  Therefore, AlloMap may make your post-transplant care easier. Since its introduction in 2005, AlloMap has helped to:

  • Reduce patients’ pain, anxiety, and risk caused by biopsies using a simple, noninvasive method of blood sample collection.1
  • Provide doctors with accurate information on their patients’ immune response following a heart transplant.

The AlloMap test provides a score, which will help your doctor assess your risk for acute cellular rejection. AlloMap is typically performed in combination with other tests to give your doctor a complete picture of your current status.

Talk to your doctor about making AlloMap testing part of your transplant care. If AlloMap is right for you, your doctor will:

  • Direct you to a local laboratory to have the blood test done
  • Have the laboratory collect, process, and send your blood sample for analysis
  • Receive your AlloMap test results usually within 2 days after your blood test

Currently, Medicare and many private insurance plans pay for AlloMap testing. CareDx has dedicated Patient Advocacy Managers who can help patients obtain coverage for AlloMap testing. If you have any questions please contact the Patient Advocacy Team at 1-866-383-1924 or email .

Your insurance company may send you an Explanation of Benefits (EOB) statement by mail.  This EOB tells you that they have been billed for AlloMap. THIS IS NOT A BILL. It is simply an explanation of the amount your insurance company was billed by CareDx for AlloMap. If you receive an EOB with an outstanding balance under “Patient Responsibility” or “You May Owe” line, please contact the Patient Advocacy Team at 1-866-383-1924.

If you have any questions at all regarding billing for the AlloMap test, please contact the Patient Advocacy Team at 1-866-383-1924 or email .

References:

  1. Deng, Mario C. et al., Utility of Gene Expression Profiling Score Variability to Predict Clinical Events in Heart Transplant Recipients. Transplantation 97.6 (2014): 708–714. PMC. Web. 1 Dec. 2015.